FDA Approves Frontline NALIRIFOX for Metastatic Pancreatic A

FDA Approves Frontline NALIRIFOX for Metastatic Pancreatic Adenocarcinoma

The FDA has approved irinotecan liposome (Onivyde) with oxaliplatin, fluorouracil, and leucovorin, for the frontline treatment of metastatic pancreatic adenocarcinoma.

Related Keywords

, Nalirifox , Irinotecan Liposome Injection , Onivyde , Metastatic Pancreatic Adenocarcinoma , Pdac ,

© 2025 Vimarsana